Last reviewed · How we verify
Lyophilized formulation of HRV vaccine
Lyophilized formulation of HRV vaccine is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of human rhinovirus infection.
A lyophilized (freeze-dried) Human Rhinovirus vaccine that stimulates the immune system to generate protective antibodies and cellular immunity against rhinovirus infection.
A lyophilized (freeze-dried) Human Rhinovirus vaccine that stimulates the immune system to generate protective antibodies and cellular immunity against rhinovirus infection. Used for Prevention of human rhinovirus infection.
At a glance
| Generic name | Lyophilized formulation of HRV vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated or attenuated human rhinovirus particles that trigger both humoral (antibody) and cell-mediated immune responses. By presenting viral antigens in a stable, lyophilized formulation, the vaccine primes the immune system to recognize and neutralize rhinovirus upon natural exposure, reducing infection severity or incidence.
Approved indications
- Prevention of human rhinovirus infection
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (PHASE3)
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine (PHASE3)
- Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants (PHASE3)
- To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lyophilized formulation of HRV vaccine CI brief — competitive landscape report
- Lyophilized formulation of HRV vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Lyophilized formulation of HRV vaccine
What is Lyophilized formulation of HRV vaccine?
How does Lyophilized formulation of HRV vaccine work?
What is Lyophilized formulation of HRV vaccine used for?
Who makes Lyophilized formulation of HRV vaccine?
What drug class is Lyophilized formulation of HRV vaccine in?
What development phase is Lyophilized formulation of HRV vaccine in?
What are the side effects of Lyophilized formulation of HRV vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of human rhinovirus infection
- Compare: Lyophilized formulation of HRV vaccine vs similar drugs
- Pricing: Lyophilized formulation of HRV vaccine cost, discount & access